FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110304911> ?p ?o ?g. }

• W2110304911 abstract "You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy and New Technology (III)1 Apr 20132178 SAFETY AND EFFECTIVENESS OF THULIUM VAPOENUCLEATION OF THE PROSTATE IN PATIENTS WITH ONGOING ORAL ANTICOAGULATION Christopher Netsch, Michael Stöhrer, Sophie Knipper, Thorsten Bach, Thomas Herrmann, and Andreas Gross Christopher NetschChristopher Netsch Hamburg, Germany More articles by this author , Michael StöhrerMichael Stöhrer Hannover, Germany More articles by this author , Sophie KnipperSophie Knipper Hamburg, Germany More articles by this author , Thorsten BachThorsten Bach Hamburg, Germany More articles by this author , Thomas HerrmannThomas Herrmann Hannover, Germany More articles by this author , and Andreas GrossAndreas Gross Hamburg, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2087AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES We evaluated the safety and efficacy of Thulium VapoEnucleation of the prostate (ThuVEP) in patients with ongoing oral anticoagulation (OA) and symptomatic benign prostatic obstruction (BPO). METHODS Fifty-six patients, undergoing ThuVEP at two institutions, were evaluated prospectively from May 2009 until June 2011. All patients were at high cardiopulmonary risk and presented with a mean American Society of Anesthesiology score of 2.7±0.5. Thirty-two patients were on aspirin, 8 were on clopidogrel or clopidogrel and aspirin, and 16 on phenprocoumon at the time of surgery. Patient demographic, perioperative, and 12-month follow-up data were analyzed. The complications were assessed. RESULTS Mean prostate volume was 57.15±30.75 cc and resected tissue weight was 37.72±22.91 gm. The mean operative time was 74.92±46.81 minutes and the catheter time 2.14±0.36 days, respectively. The mean postoperative haemoglobin decrease was 1.4±1.18 g/dL. There were no perioperative thromboembolic events. Five (8.9%) patients required a second-look operation in the immediate postoperative course (haemorrhage n=4, residual adenoma n=1) and four (7.1%) patients received blood transfusions. Complications within 30 days included urinary tract infection (n=1, 1.7%), acute urinary retention (n=2, 3.6%), and delayed bleeding (n=4, 7.1%). These complications were managed conservatively. At 12-month follow-up, Quality of Life (4.38±0.93 vs. 1.47±0.95), international prostate symptom score (20.25±5.25 vs. 5.29±3.28), maximum urinary flow rate (8.22±3.15 vs. 29.4±11.08 ml/s), and post-void residual urine (123.6±98.67 vs. 22.4±25.35 ml) improved significantly (p<0.002). None of the patients were re-treated during follow-up for recurrent prostatic tissue, urethral strictures or bladder neck contractures. CONCLUSIONS ThuVEP is a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk with ongoing OA. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e893 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Christopher Netsch Hamburg, Germany More articles by this author Michael Stöhrer Hannover, Germany More articles by this author Sophie Knipper Hamburg, Germany More articles by this author Thorsten Bach Hamburg, Germany More articles by this author Thomas Herrmann Hannover, Germany More articles by this author Andreas Gross Hamburg, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2110304911 created "2016-06-24" @default.
• W2110304911 creator A5001601094 @default.
• W2110304911 creator A5012198646 @default.
• W2110304911 creator A5015822904 @default.
• W2110304911 creator A5052627379 @default.
• W2110304911 creator A5056672566 @default.
• W2110304911 creator A5065598615 @default.
• W2110304911 date "2013-04-01" @default.
• W2110304911 modified "2023-09-25" @default.
• W2110304911 title "2178 SAFETY AND EFFECTIVENESS OF THULIUM VAPOENUCLEATION OF THE PROSTATE IN PATIENTS WITH ONGOING ORAL ANTICOAGULATION" @default.
• W2110304911 doi "https://doi.org/10.1016/j.juro.2013.02.2087" @default.
• W2110304911 hasPublicationYear "2013" @default.
• W2110304911 type Work @default.
• W2110304911 sameAs 2110304911 @default.
• W2110304911 citedByCount "0" @default.
• W2110304911 crossrefType "journal-article" @default.
• W2110304911 hasAuthorship W2110304911A5001601094 @default.
• W2110304911 hasAuthorship W2110304911A5012198646 @default.
• W2110304911 hasAuthorship W2110304911A5015822904 @default.
• W2110304911 hasAuthorship W2110304911A5052627379 @default.
• W2110304911 hasAuthorship W2110304911A5056672566 @default.
• W2110304911 hasAuthorship W2110304911A5065598615 @default.
• W2110304911 hasConcept C121608353 @default.
• W2110304911 hasConcept C126322002 @default.
• W2110304911 hasConcept C126894567 @default.
• W2110304911 hasConcept C141071460 @default.
• W2110304911 hasConcept C2776235491 @default.
• W2110304911 hasConcept C2777628954 @default.
• W2110304911 hasConcept C2777849778 @default.
• W2110304911 hasConcept C2779466945 @default.
• W2110304911 hasConcept C31174226 @default.
• W2110304911 hasConcept C71924100 @default.
• W2110304911 hasConceptScore W2110304911C121608353 @default.
• W2110304911 hasConceptScore W2110304911C126322002 @default.
• W2110304911 hasConceptScore W2110304911C126894567 @default.
• W2110304911 hasConceptScore W2110304911C141071460 @default.
• W2110304911 hasConceptScore W2110304911C2776235491 @default.
• W2110304911 hasConceptScore W2110304911C2777628954 @default.
• W2110304911 hasConceptScore W2110304911C2777849778 @default.
• W2110304911 hasConceptScore W2110304911C2779466945 @default.
• W2110304911 hasConceptScore W2110304911C31174226 @default.
• W2110304911 hasConceptScore W2110304911C71924100 @default.
• W2110304911 hasIssue "4S" @default.
• W2110304911 hasLocation W21103049111 @default.
• W2110304911 hasOpenAccess W2110304911 @default.
• W2110304911 hasPrimaryLocation W21103049111 @default.
• W2110304911 hasRelatedWork W1444716854 @default.
• W2110304911 hasRelatedWork W164835667 @default.
• W2110304911 hasRelatedWork W1999940036 @default.
• W2110304911 hasRelatedWork W2080681036 @default.
• W2110304911 hasRelatedWork W2089408780 @default.
• W2110304911 hasRelatedWork W2123607882 @default.
• W2110304911 hasRelatedWork W2435339303 @default.
• W2110304911 hasRelatedWork W2597068225 @default.
• W2110304911 hasRelatedWork W3029421250 @default.
• W2110304911 hasRelatedWork W2527719101 @default.
• W2110304911 hasVolume "189" @default.
• W2110304911 isParatext "false" @default.
• W2110304911 isRetracted "false" @default.
• W2110304911 magId "2110304911" @default.
• W2110304911 workType "article" @default.